FDA Draft Guidances Assert Oversight Over Multiplex Tests
This article was originally published in The Gray Sheet
Executive Summary
CDRH is asserting its oversight authority in the development and use of high-tech tests that may fall through the cracks of current premarket practices via the release of two draft guidances Sept. 7